Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Mallinckrodt
Citi
Healthtrust
Queensland Health
Cantor Fitzgerald
Julphar
Teva
Daiichi Sankyo

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,034,054

« Back to Dashboard

Which drugs does patent 6,034,054 protect, and when does it expire?


Patent 6,034,054 protects HUMALOG KWIKPEN and is included in one NDA.

This patent has thirty-eight patent family members in thirty countries.

Summary for Patent: 6,034,054

Title: Stable insulin formulations
Abstract:The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.
Inventor(s): DeFelippis; Michael Rosario (Indianapolis, IN), Dobbins; Michael Allen (Lebanon, IN), Frank; Bruce Hill (Indianapolis, IN), Li; Shun (Indianapolis, IN), Rebhun; Dawn Marie (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/096,247
Patent Claim Types:
see list of patent claims
Formulation; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Eli Lilly And CoHUMALOG KWIKPENinsulin lispro recombinantSOLUTION;SUBCUTANEOUS205747-001May 26, 2015RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.
Eli Lilly And CoHUMALOG KWIKPENinsulin lispro recombinantSOLUTION;SUBCUTANEOUS205747-001May 26, 2015RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,034,054

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,551,992 Stable insulin formulations► Subscribe
6,906,028 Stable insulin formulations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,034,054

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan577753► Subscribe
Turkey9903036► Subscribe
El Salvador1998000065► Subscribe
SloveniaEP0884053► Subscribe
Portugal1283051► Subscribe
Portugal884053► Subscribe
Poland194244► Subscribe
Poland337324► Subscribe
Peru79099► Subscribe
New Zealand501382► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
UBS
Argus Health
Daiichi Sankyo
Citi
Chinese Patent Office
Chubb
Cerilliant
Merck
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot